About Us
SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of 11 pre-clinical drug candidates over the last five years. Milestone payments have resulted as these compounds progressed through development at our partners.
Our expertise is offered on a fee for service basis or may be conducted in a shared risk arrangement. SCYNEXIS' teams are tailored to be especially effective in moving customer projects from concept to clinic, utilizing powerful proprietary technologies such as the HEOS® Data Management and Collaboration Software Suite and the MEDCHEM-FACTORY® High-Throughput Synthesis and Purification Platform.
Our fully-integrated contract research solutions include medicinal chemistry, advanced biological screening, in vitro pharmacology and ADMET, DMPK, bioanalytical and analytical chemistry, process chemistry, and cGMP manufacturing. The SCYNEXIS process chemistry department recently passed a general inspection and pre-approval inspection (PAI) by the FDA in support of a customer's NDA.
Founded in 2000, SCYNEXIS is located in Research Triangle Park, N.C. and occupies more than 120,000 sq.ft of laboratory and office space strategically located in close proximity to RDU International Airport, GSK, IBM, and Cisco and central to the campuses of UNC Chapel Hill, Duke University and NC State University. SCYNEXIS is registered with both the FDA and DEA. For more information, please visit www.scynexis.com.
Our expertise areas include:
- Fully-Integrated Drug Discovery & Development Programs
- Contract Research & Development Capabilities
- Chemical Process Development & GMP Manufacturing
- Medicinal Chemistry & Lead Optimization
- Bioanalytical & ADMET Services
- Analytical Method Development & Validation
- HEOS Data Management & Collaboration Software
Success with SCYNEXIS
Our team of more than 120 scientific experts, nearly half of whom hold Ph.D. degrees, has successfully delivered 11 preclinical and clinical candidates for our customers and global partners. This expertise is offered on a fee-for-service or shared-risk basis. Our global client base has benefited from the diverse therapeutic expertise areas of SCYNEXIS Research Team Leaders. We have been involved in drug discovery, development or manufacturing projects in numerous areas including:
|
|
SCYNEXIS Capabilities Overview Contract Research & Development Capabilities
Our research capabilities include:
|
Our development capabilities
include:
|
Medicinal Chemistry & Lead Optimization
SCYNEXIS' medicinal chemistry group has a reputation equaling the best in the industry. Our team has the size and experience to handle projects of any complexity in a wide range of therapeutic areas. The Research Team leaders are knowledgeable scientists with years of industry experience. They coordinate and communicate key activities and drive resources to achieve success. The teams are enabled with SCYNEXIS' powerful proprietary technologies such as KIT™ Kinase Inhibitor Technology , HEOS® Software Suite and MEDCHEM-FACTORY®.
- HEOS® (Hit Explorer Operating System): Comprehensive web-based chemical information management software
- ADME/PK: Bioavailability, stability and Cyp450 information is available from our in-house capability
- KIT™ (Kinase Inhibitor Technology): Leverages structural information to define binding modes
- Computational Chemistry: Predictive physiochemical properties, homology modeling and receptor docking, QSAR
- MEDCHEM-FACTORY®: High-throughput synthesis and purification
Chemical Process Development & GMP Manufacturing
The SCYNEXIS Process Development team consists of approximately 25 scientific experts with an average of 20 years of industry experience. 12 of the team members hold Ph.D.'s and we maintain an even balance between process and analytical team members.
cGMP Manufacturing Suites & non-GMP Kilo Facilities:
- 3 separate GMP Suites
- Controlled access, dedicated air handling
- GMP Reactors: 25 L to 200 L QVF glass fixed reactors
- Huber chillers/heaters
- QA Audited, Expecting PAI in 2009
- Versatile non-GMP facilities
- Non-GMP Reactors: 20 L to 200 L QVF glass fixed reactors
- 6" Biotage chromatography systems
SCYNEXIS' Process Chemistry team has outstanding analytical support. We have in-house 400 and 500 MHz NMRs, LC-MS and LC-MS/MS, FT-IR, HPLC, GC, K-F, TOC and dedicated experts to assist in method development, validation and impurity identification.
Today's pharmaceutical environment demands rugged, sensitive and specific analytical methods to support FDA regulatory filings. SCYNEXIS has demonstrated success in developing and validating analytical methods for API's intended for Phase I clinical trials through NDA submission. We understand the API development industry and continually strive to meet our clients' most critical deadlines. Our team works in state-of-the-art facilities with access to a comprehensive suite of cutting edge analytical instrumentation. Highly sensitive genotoxic impurity methods have been developed for numerous clients and we have performed full API release testing for more than 50 programs. A broad array of analytical platforms and techniques is available:
|
|
Analytical service offerings include:
|
|
|
Bioanalytical & ADMET-PK Services SCYNEXIS provides rapid generation of reliable ADMET and pharmacokinetics (PK) on compounds with a focus on lead optimization integrated with medicinal chemistry teams. SCYNEXIS rapidly screens for properties including metabolic stability (complemented with specific CYP450 assays), permeability, transporters, protein binding and cytotoxicity to prioritize and optimize lead series based on ADMET properties. Secure timely web-based data exchange (HEOS®). |
|
Bioanalytical Capabilities
|
In Vitro
ADMET Capabilities
|
In
Vivo ADME Studies
|
HEOS® Data Management & Collaboration Software
HEOS® suite is a comprehensive web-based Drug Research information management software that supports geographically distributed scientists and facilitate collaboration.
HEOS® is seamlessly integrated to "best" scientific expert software currently used in the Pharmaceutical Industry. It allows complex data (biology, chemistry, analytical, safety, PK...) to be exchanged, consolidated and shared rapidly and securely across multi-sites worldwide. It provides powerful searching capabilities to combine substructure and biological criteria, interactive SAR capabilities and decision tools to scientists and management.
Data Management:
- Comprehensive acquisition, organization and display of various types of information relevant to Drug Discovery projects: chemistry, analytical, biological assays, animal assays, ADME, Toxicology, Pharmacokinetics, etc.
- Powerful chemical-biological searching capabilities, including substructure searching
- Interactive SAR capabilities
- Flexible export to third-party software such as SpotFire for further data analysis
Collaboration:
- Secure access through a web interface with access-control to the data
- Easy publication of results from each project member
- Share decision-making reports
- Securely exchange key project documents

SCYNEXIS, Inc.
P.O. Box 12878
Research Triangle Park, NC 27709
UNITED STATES
Phone: 919.544.8603
Fax: 919.544.8697
Contact: Terry Marquardt
Hot Products
- SCYNEXIS’ anti-HCV Compound SCY-635 Restores Innate Immune Response to HCV, Possibly Replacing Interferon
- Analytical Method Development and Validation
- cGMP Synthesis and Contract Manufacturing Services
- ADMET-PK and Bioanalytical Services
- High Throughput Purification and Analysis
- Custom Synthesis and API Intermediates
- Process Chemistry and Optimization Services
- HEOS® Drug Discovery Software Suite
- Medicinal Chemistry and Drug Discovery Services
- Bioanalytical Services
Featured Articles
- SCYNEXIS Collaborates with PharmaDirections to Produce TAU Therapeutics’ Cancer Drug, Mibefradil
- White Paper: Benzoxaboroles: A New Potential Drug for African Sleeping Sickness
- SCYNEXIS & Innovative Vector Control Consortium (IVCC) Drug Discovery Collaboration
- White Paper: Tetracycline Antibiotics
- White Paper: Tetracycline Antibiotics
- Press Release: SCYNEXIS-Anacor-DNDi: An Innovative Partnership Advances Novel Drug to Combat Sleeping Sickness
- SCYNEXIS-Anacor-DNDi: An Innovative Partnership Advances Novel Drug to Combat Sleeping Sickness
- SCYNEXIS and TB Alliance Sign HEOS Drug Discovery Software Agreement
- Scynexis and TB Alliance Agreement For Heos Drug Discovery Software
- Case Study: Informatics For Neglected Diseases Collaborations
- Case Study: Informatics For Neglected Diseases Collaborations
- Video: Scynexis At AAPS 2010
- SCYNEXIS Introduces Application For Mobile Access To HEOS Information System
- SCYNEXIS Receives Four Federal Therapeutic Discovery Grants
- SCYNEXIS Receives Merial Research Collaboration Milestone Payment
- SCYNEXIS Announces Presentations Of Data From Anti-Fungal Drug Candidate At The 50th ICAAC Meeting
- SCYNEXIS And Trevena Announce Strategic Collaboration To Enhance Discovery Of Biased GPCR Ligands
- SCYNEXIS cGMP Facilities Audited By FDA - No Form 483 Observations Issued
- SCYNEXIS, Inc. Receives Milestone Payment From Collaboration With Merck & Co., Inc.
- SCYNEXIS Receives Merial Research Collaboration Milestone Payment

